ATE303154T1 - Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv - Google Patents

Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv

Info

Publication number
ATE303154T1
ATE303154T1 AT00971704T AT00971704T ATE303154T1 AT E303154 T1 ATE303154 T1 AT E303154T1 AT 00971704 T AT00971704 T AT 00971704T AT 00971704 T AT00971704 T AT 00971704T AT E303154 T1 ATE303154 T1 AT E303154T1
Authority
AT
Austria
Prior art keywords
trifluridine
hiv
phosphorylase inhibitor
thymidine phosphorylase
treatment
Prior art date
Application number
AT00971704T
Other languages
English (en)
Inventor
Hiroo Hoshino
Kenji Kitazato
Masakazu Fukushima
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE303154T1 publication Critical patent/ATE303154T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT00971704T 1999-11-05 2000-11-01 Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv ATE303154T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP31567099A JP4110347B2 (ja) 1999-11-05 1999-11-05 抗ｈｉｖ剤
PCT/JP2000/007676 WO2001034162A1 (en) 1999-11-05 2000-11-01 Anti-hiv compositions

Publications (1)

Publication Number Publication Date
ATE303154T1 true ATE303154T1 (de) 2005-09-15

Family

ID=18068171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00971704T ATE303154T1 (de) 1999-11-05 2000-11-01 Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv

Country Status (6)

Country Link
US (1) US6596720B1 (de)
EP (1) EP1230925B8 (de)
JP (1) JP4110347B2 (de)
AT (1) ATE303154T1 (de)
DE (1) DE60022380T2 (de)
WO (1) WO2001034162A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091990A1 (en) * 2001-09-17 2003-05-15 Cloyd Miles W. Methods and compositions involving thymidine phosphorylase as a marker for HIV infection, aids progression, and drug resistance
CN100379750C (zh) 2002-08-21 2008-04-09 阿尔伯爱因斯坦医科叶希瓦大学 核苷磷酸化酶和核苷酶抑制剂
RU2435587C2 (ru) 2006-06-30 2011-12-10 Тайхо Фармасьютикал Ко., Лтд. Средство, потенцирующее радиационную терапию
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
CA2676551C (en) 2007-01-31 2015-12-22 Biosuccess Biotech Company Compositions and methods of use of phorbol esters
TWI435725B (zh) * 2007-10-11 2014-05-01 Taiho Pharmaceutical Co Ltd The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis
TWI429439B (zh) * 2007-10-11 2014-03-11 Taiho Pharmaceutical Co Ltd And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
AU2013233226B2 (en) 2012-03-14 2016-05-19 Nisshin Pharma Inc. Sulfur amino acid-containing composition
MA38668B2 (fr) 2013-06-17 2019-09-30 Taiho Pharmaceutical Co Ltd Cristal stabilisé de chlorhydrate de tipiracil, et son procédé de cristallisation
CN103980253B (zh) * 2014-05-06 2015-07-08 济南百诺医药科技开发有限公司 一种5-氯-6-(2-亚氨基吡咯烷基-1-基)甲基-2,4-(1h, 3h)嘧啶二酮盐酸盐的合成方法
CN106317028A (zh) * 2015-11-03 2017-01-11 江苏悦兴药业有限公司 抗肿瘤药物盐酸替比拉西的制备方法及其关键中间体
CN112569250A (zh) * 2020-10-16 2021-03-30 中山大学 三氟尿苷制备hiv-1药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129984B1 (de) * 1983-05-23 1988-03-02 Taiho Pharmaceutical Company Limited 2'-Desoxy-5-substituierte Uridin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Antitumor- Zusammensetzungen
WO1987004929A1 (en) * 1986-02-20 1987-08-27 Greer Sheldon B Composition for and method of treating aids and certain related diseases
ATE72122T1 (de) * 1987-04-24 1992-02-15 Wellcome Found Antivirale mischungen.
CA2033447C (en) * 1990-12-31 1999-08-31 Robert Deziel Synergistic combination for treating herpes infections
CA2033448C (en) * 1990-12-31 1996-11-26 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Antiherpes compositions and method of use
DE69629156T2 (de) * 1995-03-29 2004-05-06 Taiho Pharmaceutical Co. Ltd. Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
JP4049477B2 (ja) * 1999-03-23 2008-02-20 大鵬薬品工業株式会社 副作用軽減剤

Also Published As

Publication number Publication date
JP2001131075A (ja) 2001-05-15
EP1230925A4 (de) 2004-06-09
WO2001034162A1 (en) 2001-05-17
US6596720B1 (en) 2003-07-22
JP4110347B2 (ja) 2008-07-02
EP1230925B8 (de) 2006-03-01
EP1230925B1 (de) 2005-08-31
EP1230925A1 (de) 2002-08-14
DE60022380T2 (de) 2006-06-08
DE60022380D1 (de) 2005-10-06

Similar Documents

Publication Publication Date Title
ATE303154T1 (de) Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
HN1996000017A (es) Isotiazolonas
DE60000992D1 (de) Desinfizierende zusammensetzung auf basis von h2o2, säuren und metallionen
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
TR200200068T2 (tr) Nematisital triflüorobütenler
DE69316751D1 (de) Azlaktonfunktionen aufweisende substrate, hornhautprothesen und ihre verwendung
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
BR9902457A (pt) Padrões de adesivo aperfeiçoados para artigos de higiene feminina.
DE69403656D1 (de) Stabile, orale und absorbierbare therapeutische zusammensetzungen von nadh und nadph
DE60013859D1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
DK0768086T3 (da) Behandling af tinnitus med neurobeskyttende virksomme stoffer
NO934706L (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
EP1319402A4 (de) IgE-ENTSTEHUNGSHEMMSTOFFE
ES2060918T3 (es) Derivados de ciclopropilo que poseen actividad inhibidora lipoxigenasa.
FI945164A0 (fi) Biologisesti aktiivisesti ureidojohdannaiset, jotka ovat käyttökelpoisia antimetastaattisina aineina
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
DE69834057D1 (de) Echinocandinderivate, deren herstellung und deren verwendung zur bekämpfung von pilzen
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
UA37251C2 (uk) Лікарський засіб для лікування або профілактики вірусної інфекції гепатиту в і спосіб лікування вірусної інфекції гепатиту в
EP0979650A4 (de) Antivirus mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties